0001214659-21-012329.txt : 20211126
0001214659-21-012329.hdr.sgml : 20211126
20211126171520
ACCESSION NUMBER: 0001214659-21-012329
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211123
FILED AS OF DATE: 20211126
DATE AS OF CHANGE: 20211126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jordan Edward P.
CENTRAL INDEX KEY: 0001600814
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35798
FILM NUMBER: 211452255
BUSINESS ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 6174982850
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 1100 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER NAME:
FORMER CONFORMED NAME: Edward P. Jordan
DATE OF NAME CHANGE: 20140221
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HUMANIGEN, INC
CENTRAL INDEX KEY: 0001293310
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770557236
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 533 AIRPORT BLVD.
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 650.243.3100
MAIL ADDRESS:
STREET 1: 533 AIRPORT BLVD.
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
FORMER COMPANY:
FORMER CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20040609
4
1
marketforms-54401.xml
PRIMARY DOCUMENT
X0306
4
2021-11-23
0001293310
HUMANIGEN, INC
HGEN
0001600814
Jordan Edward P.
C/O HUMANIGEN, INC.
533 AIRPORT BOULEVARD, SUITE 400
BURLINGAME
CA
94010
false
true
false
false
Chief Commercial Officer
Stock Option (Right to Buy)
5.93
2021-11-23
4
D
false
4966
4.53
D
2021-10-31
2031-09-30
Common Stock
4966
0
D
As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 25% of his base salary for the fourth quarter of 2021, or $22,485. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model.
/s/ Timothy E. Morris, Attorney-in-fact
2021-11-26